Detalhe da pesquisa
1.
Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
Oncologist
; 22(11): 1301-1308, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28701571
2.
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Oncologist
; 21(2): 150-5, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26786263
3.
Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy.
Acta Radiol
; 56(11): 1300-7, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25348477
4.
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Oncologist
; 21(6): 778, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27317735
5.
Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register.
Breast Cancer Res Treat
; 122(2): 591-600, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20063196
6.
Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model.
Gac Sanit
; 34(1): 61-68, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442434
7.
A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.
Clin Cancer Res
; 14(3): 811-6, 2008 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18245543
8.
Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals.
Clinicoecon Outcomes Res
; 10: 189-199, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29593426
9.
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
JAMA Oncol
; 4(3): 302-308, 2018 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29327055
10.
Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases.
F1000Res
; 6: 1606, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29862012
11.
A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.
Clin Cancer Res
; 23(12): 3035-3044, 2017 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27903675
12.
Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel.
Breast Care (Basel)
; 11(2): 133-8, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27239176
13.
Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.
Curr Cancer Drug Targets
; 16(5): 415-28, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26278712
14.
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
J Clin Oncol
; 33(32): 3788-95, 2015 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26416999
15.
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
J Clin Oncol
; 31(20): 2593-9, 2013 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23733779
16.
Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma.
Eur J Cancer
; 45(5): 732-5, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19186051
17.
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
J Natl Cancer Inst
; 100(11): 805-14, 2008 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-18505968
18.
Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM).
Breast Cancer Res Treat
; 101(2): 215-23, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16823507